The HPV vaccine helps protect against 6 types of cancer. It prevents infection by high-risk types of human papillomavirus, or HPV, that cause the majority of cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers (cancers of the throat and tongue) and genital warts. The American Cancer Society is on a mission to help prevent HPV cancers by working in partnership with health professionals and organizations in the United States and around the world.
Each year, almost 35,000 people are diagnosed with HPV-related cancers – cancers that can largely be prevented through vaccination. While more than 60% of boys and girls in the U.S. get the first dose of the HPV vaccine, too many fail to get the full vaccination series. This means they are not getting the protection against cancer that the vaccine provides.
We work at the national, state, and community level to increase HPV vaccination uptake through education, awareness, and partnerships. Our initiatives seek to advance best practices, support clinic-based interventions, and increase collaboration and leadership among key partners to push the prioritization of the vaccine.
Access current guideline information from the American Cancer Society.
Members of the National HPV Vaccination Roundtable's Provider Training Task Group developed a suite of 6 Clinician & System Action Guides to encourage providers, support teams, and health systems to take action today.
An action guide for implementing evidence-based interventions in the clinical setting.